Angiodynamics reports fiscal year 2025 third quarter financial results

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2025, which ended february 28, 2025. fiscal year 2025 third quarter highlights   quarter ended february 28, 2025 pro forma* yoy growth pro forma* net sale.
ANGO Ratings Summary
ANGO Quant Ranking